Render Target: STATIC
Render Timestamp: 2024-11-01T10:02:21.551Z
Commit: 23cb9f61fe67e1e9093fd644a533c4ff516a6463
XML generation date: 2024-09-20 06:23:27.962
Product last modified at: 2024-08-30T22:45:07.511Z
1% for the planet logo
PDP - Template Name: Chemical Modulators
PDP - Template ID: *******c501c72

Mitochondrial Fusion Promoter M1 #55199

    Product Information

    Product Usage Information

    Mitochondrial Fusion Promoter M1 is supplied as a lyophilized powder. For a 15 mM stock, reconstitute 5 mg of powder in 0.92 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.

    Storage

    Store lyophilized at room temperature, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 2 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

    Product Description

    Molecular Weight 364.1 g/mol
    Purity >98%
    Molecular Formula C14H10Cl4N2O
    CAS 219315-22-7
    Solubility Soluble in DMSO at 40 mg/mL or ethanol at 6 mg/mL.

    Background

    Mitochondrial Fusion Promoter M1 is a hydrazone compound that promotes mitochondrial fusion in fragmented mitochondria (1). In a study of human induced pluripotent stem cells (iPSCs), M1 fused fragmented mitochondria and promoted the differentiation of iPSCs into an early mesodermal cardiac lineage (2). Pancreatic β cells treated with soluble cholesterol triggers increased total cholesterol accumulation, diminished cellular respiration, and compromised glucose-stimulated insulin secretion. Treatment of these cells with M1 prevents cholesterol-mediated suppression of cellular respiration and increases glucose-stimulated insulin secretion (3). M1 is also seen to protect against brain damage in rats with induced cardiac ischemia/reperfusion (I/R) injury (4) and against diabetic cardiomyopathy in a rat model of diabetes (5). Treatment of donor microvascular endothelial cells with M1 and the fission inhibitor Mdivi1 promotes mitochondrial fusion and reduces recipient T cell responses, which may lead to improved cardiac transplant survival (6).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.